Introduction
Lung cancer is the leading cause of death in the United States with projected 171 500 people to die from this disease in 1998 (Parker et al., 1997) .
Abnormalities in oncogenes, such as Ras (Slebos and Rodenhuis, 1992), Myc (Prins et al., 1993) , Bcl-2 (Pezzella et al., 1993) and c-Erb-2 (Kern and Filderman, 1993) and tumor suppressor genes, such as Rb (Carbone and Kratzke, 1996) , p53 (Sidransky and Hollstein, 1996) , p16
INK4A (Shapiro et al., 1995) , may contribute to the pathogenesis of this devastating disease. The abnormalities in lung cancer may also re¯ect changes in the cytoskeleton and cytoskeleton associated proteins. Previously, it has been shown that transforming oncogenes such as v-src (Brown and Cooper, 1996) , v-crk (Birge et al., 1993) , BCR/ABL , and E6 (bovine and human papilloma virus) (Tong and Howley, 1997) interact with the cytoskeleton in oncogenesis. It is therefore possible that the various molecular abnormalities in lung cancer also contribute to transformation via the cytoskeleton.
The cytoskeleton is composed of multiple parts and it is the actin cytoskeleton which is involved in regulation of cell shape, cell motility and adhesion. The deregulation of cytoskeletal function contributes to transformation . The actin cytoskeleton interacts with the extracellular matrix and intracellular molecules via the focal adhesion. The focal adhesion contains proteins such as tensin and vinculin (Coll et al., 1995) which are thought to also have tumor suppressor properties. Focal adhesion proteins are also key regulators of some signal transduction events (Weisberg et al., 1997) .
Paxillin, a 68 kDa protein with four tandem LIM domains and multiple serine/tyrosine phosphorylation sites, is a unique focal adhesion protein with its ability to interact with certain oncogenes (Salgia et al., 1995b; Turner, 1994) . Paxillin is tyrosine phosphorylated in response to oncogenes such as v-src (Schaller and Parsons, 1994) , v-crk (Birge et al., 1993) and BCR/ABL (Salgia et al., 1995a) . This focal adhesion protein is tyrosine phosphorylated in response to growth factors such as PDGF/EGF (Rankin et al., 1996) , IL-3 and steel factor (Salgia et al., 1995b) , and neuropeptides such as bombesin (Charlesworth et al., 1996) . b1 and b2 integrin activation on the cell surface also lead to phosphorylation of paxillin (Charlesworth et al., 1996) . Multiple kinases, including p125 FAK and RAFTK, can directly interact with paxillin (Salgia et al., 1996a) .
To better de®ne the cytoskeletal abnormalities in lung cancer, we evaluated the expression of paxillin in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Paxillin localized to focal adhesions with vinculin in lung cancer cell lines, and overexpression of full length paxillin in NSCLC cell lines causes cells to round up and become less motile. It is also shown here that there is paxillin expression in NSCLC cell lines and patient tumor tissue samples, with only a few tumors having abnormal paxillin expression. Whereas, there was a generalized relative decrease in expression of paxillin in SCLC ± both cell lines and tumor specimens.
Results

Localization of paxillin in focal adhesions in lung cancer cell lines
Previously, it had been shown that paxillin and vinculin localize to the focal adhesions of several adherent cell lines, such as mouse NIH3T3 and human FS-2 cells. We have performed cell staining for paxillin and vinculin in the human diploid lung line MRC-5 and various NSCLC cell lines (Calu-1 and SK-LU-1) (Figure 1 ). Using the anti-paxillin antibody 5H11, paxillin is localized to the focal adhesion in these cells (Salgia et al., 1996a) . As a control, vinculin is in the focal adhesions as expected. This is also true for all NSCLC cell lines described in this paper (data not shown).
In contrast to NSCLC, SCLC are much smaller cells and the actin and vinculin staining pattern is diuse (data not shown). There was no staining seen with paxillin in SCLC cell lines.
Paxillin overexpression causes cell morphology and motility changes in NSCLC
Since paxillin appears to be expressed in adherent cell lines, we determined if there was any eect on cell morphology and cell motility by overexpression in NSCLC cell lines (calu-1 and H661). To determine the eects of overexpression of paxillin, we have constructed GFP-paxillin, GFP-PE7 (containing the N-terminus of paxillin), and GFP-LIM domains of paxillin. As seen in Figure 2 , by overexpression, GFP-paxillin and GFP-PE7 during the ®rst 24 h are localized to the cytoplasm; whereas GFP-LIM is localized both to the nucleus and cytoplasm. As a control, GFP alone is also both nuclear and cytoplasmically localized.
During the overexpression studies, when the transient transfections were observed for a 48 h or longer, the GFP-paxillin overexpressed cells became round and under time-lapse videomicroscopy had less membrane ruing with less lamellipodia and ®lopodia and decreased migration. As controls, there was no change seen in cell morphology or cell motility in GFP-PE7, GFP-LIM or in the GFP overexpressed cells. These experiments have been performed at least ®ve times each in Calu-1 and H661 NSCLC cell lines with the same results. Using another vector pRC/CMV and the various paxillin constructs, to study cell morphology and cell motility, the results were exactly the same as using the GFP vector (data not shown).
The same experiments were performed in SCLC cell lines (as shown in Figure 3 ). It is appreciated that Figure 4 ). Inter-blot variability did not aect the observations. The membrane was processed for northern analysis using cDNAs of paxillin, CRKL and b-actin-speci®c probes sequentially. Expression of paxillin was found in the NSCLC cell lines; and in the SCLC cell lines, the expression of paxillin was lower as compared to NSCLC cell lines. As controls, CRKL (Salgia et al., 1995c) and b-actin were expressed in all cell lines at a consistent level. Western blot analysis was also used to determine the expression of paxillin and several other focal adhesion proteins in NSCLC and SCLC cell lines ( Figure 5 ). For both the NSCLC and SCLC cell lines, talin and vinculin expression was similar in all cell lines. CRKL was also expressed at consistent levels, and in the SCLC cell lines there was a doublet at 39 kDa for CRKL which may indicate phosphorylation of CRKL in these SCLC cell lines. The protein expression of paxillin was variable in the NSCLC cell lines with very low levels in 3/5 SCLC cell lines. Paxillin expression is lower, on average, in SCLC cell lines. The cell lines MRC-5, Calu-1, Calu-6, SK-LU-1, SW900 showed high levels of expression, while Calu-3 and H69 expressed an intermediate amount, and the H520, H661, H128 cell lines expressed very low levels of paxillin. In the NSCLC cell lines the p68 band of paxillin was the dominant band, with some expression of the lower bands of paxillin (p46 and p33). As shown previously, the p46 and p33 forms may be degradation forms of p68 paxillin Yamaguchi et al., 1994) . In the SCLC cell lines, the dominant paxillin band was the p46 form. The p68 and p33 forms of paxillin in SCLC cell lines was expressed at very low levels.
Since the phosphorylation of paxillin may be important in its function, we determined the tyrosinephosphorylation of paxillin in various cell lines. Using three NSCLC and three SCLC cell lines, there was no appreciable tyrosine phosphorylation of paxillin ( Figure 6 ).
Expression of paxillin in NSCLC lung cancer patient samples and decreased expression in SCLC patient samples
Expression of paxillin was determined using Northern blot analysis and Western blot analysis in NSCLC patient samples. Both tumor samples and adjacent normal samples from the same lung were utilized for northern analysis and RNA probed using paxillin and b-actin-speci®c probe sequentially ( Figure 7) . Only a few adenocarcinoma, squamous, and large cell patient samples showed a variability in the expression of paxillin as compared with normal controls. The dierences between lung cancer samples and adjacent normal lung samples varied as much as between dierent patients. As shown in Figure 7 , one adenocarcinoma patient sample (#6) and one squamous cell lung cancer patient sample (#12) showed decreased paxillin expression as compared to normal control. In large cell cancer sample, four patient samples (#18, 19, 20, 21) had decreased paxillin expression and four samples (#17, 22, 23, 24) had increased paxillin expression in tumor tissue as compared to normal controls.
Western blot analysis was also used to determine protein expression of paxillin in patient samples with NSCLC ( Figure 8 ). In the patient samples 1/4 adenocarcinoma; 4/4 squamous lung cancer; and 0/4 large cell lung cancer expressed paxillin at dierent levels as compared to normal controls. In the patient samples, the p68 paxillin form appears to be the dominant protein expressed. Even though in cell lines, there was some level of expression of p46 and p33 forms, in patient samples these forms are not as highly expressed. As a control, expression of CRKL was shown to be consistent in the various patient protein samples. The numbers represent individual patients. Northern blot analysis of the same tissue as Western was not performed secondary to limited availability of tissue.
Finally, immunoperoxidase staining was used to determine expression of paxillin in patient tissue samples (especially SCLC). Both SCLC and NSCLC samples were used. The tissues were stained with antipaxillin, anti-keratin and hematoxylin and eosin (H&E) (Figure 9 ). By immunohistochemistry, paxillin was shown to localize into cytoplasm. Lung cancer samples were positive for keratin staining, which is used as a positive control. The NSCLC tissue sample showed a localized cytoplasmic pattern for the paxillin staining, while the SCLC tissue sample showed no paxillin staining at all. We have determined immunoperoxidase staining in ®ve separate NSCLC and SCLC patient samples each with the same results. We have seen positive reactivity with paxillin in NSCLC, whereas in the ®ve SCLC patient samples, there is no reactivity.
Discussion
Lung cancer is a devastating illness with a plethora of abnormalities at the molecular level. With abnormalities of oncogenes and tumor suppressor genes, there are eventual abnormalities of the cytoskeleton.
Changes in the cytoskeleton are very important in the carcinogenesis of lung cancer. Many cytoskeletal associated proteins have putative tumor suppressor functions. However, how cytoskeletal proteins in various tumors are expressed is just beginning to be characterized. A focal adhesion protein which may be a key regulator of oncogenesis is paxillin (Salgia et al., 1995b) .
Previous groups have shown that both paxillin and vinculin localize to the focal adhesions of adherent cell lines (Turner, 1994) . In NSCLC cell lines, we show that both paxillin and vinculin localize to focal adhesions. We show in this study that in GFPpaxillin overexpressed cells, localization was to the cytoplasm, while the GFP-LIM and GFP control localized to both the nucleus and the cytoplasm. After 48 h, the GFP-paxillin transfected cells were seen to round up, whereas the GFP-LIM and GFP control transfected cells expressed no change in morphology. Cell motility, as assessed by migration, membrane ruing, and formation of lamellipodia and ®lopodia was inhibited by paxillin overexpression in lung cancer cell lines.
The cytoskeleton is very important in cell motility. The degradation and reformation of the actin cytoskeleton in lamellipodia and ®lopodia helps the cell move along the basement membrane (Lauffenburger, 1996) . In normal cells, the cytoskeleton is very stable and there is little movement of cells. In cells which have become cancerous, the cytoskeleton is disrupted in such a way as to increase the motility of the cell . The normal cell will ®rmly attach to the membrane and stay in one place, while cancerous cells will increase their movement along the basement membrane due to a loss of a normal cytoskeleton. Previously it has been shown that metastatic lung cancers show changes in their cytoskeletal arrangement, such as a reduction in the amount of F-actin and a decrease in the integrity of the cytoskeleton itself (Ambros et al., 1975; Bernal et al., 1983) . F-actin has been shown to collect at the periphery of the cell and in some outgrowths. Metastasizing cells tend not to form clusters and exhibit no cell-to-cell contacts, which is the opposite of normally functioning cells. The observation that overexpression of paxillin causes adherent epithelial NSCLC to change morphology with decreased motility may lead to further insights on the role of paxillin in normal and transformed cells. Paxillin is one of few cytoskeletal proteins that has been recently shown to interact with growth factor receptors, integrins, and certain oncogenes. The paxillin protein was originally identi®ed in Rous sarcoma virus-transformed chick embryo ®broblasts using a monoclonal antibody produced by Glenney and Zokas (1989) . The protein has been cloned from human and chicken cells and proved to have an interesting structure; It has an N-terminus with many sites for interaction with proteins containing SH2 and SH3 domains, and a C-terminus that contains four tandem LIM domains (Salgia et al., 1995b; Turner and Miller, 1994) . Paxillin localizes to focal adhesions where it interacts with several other proteins that also localize to this region of the cell. Tensin, talin, vinculin, and the unique tyrosine kinases p125 FAK and RAFTK are but a few proteins that interact with paxillin at the focal adhesions (Bockholt and Burridge, 1993; Salgia et al., 1996a,b; Schaller et al., 1995) . Paxillin can be tyrosine phosphorylated in response to many oncogenic factors, such as v-src, v-crk, BCR/ABL and HPV/BPV E6 (Bockholt and Burridge, 1995; Glenney and Zokas, 1989; Salgia et al., 1995b; Tong and Howley, 1997) . Also, cytoplasmic kinases, growth factors, and b1 and b2 integrin crosslinking causes paxillin to be phosphorylated (Schaller et al., 1995) . This phosphorylation facilitates the interactions between paxillin and several other proteins in the focal adhesions. In addition to the 68 kDa paxillin protein (designated a form), Mazaki et al., (1997) paxillin, b and g. Isoforms b and g have distinct amino acid insertions at the same site on paxillin. The b isoform was found to bind ®rmly to FAK but weakly to vinculin, while the g isoform exhibited the reverse binding pattern. The mRNA of isoforms b and g were not detected in normal tissue, however several cancer cell lines express both a and b isoforms simultaneously.
Paxillin expression in NSCLC and SCLC cell lines and patient samples was also determined for possible role towards carcinogenesis. In the dierent types of NSCLC ± adenocarcinoma, squamous lung cancer, and large cell lung cancer ± there was no consistent overexpression or underexpression of paxillin as compared to normal controls. The expression of paxillin was very low or non-existent in SCLC samples. Again, this may be important because SCLC tends to have dierent clinical and molecular biology characteristics as compared to NSCLC. SCLC are non-adherent cell lines of neuroendocrine origin, whereas NSCLC are adherent cell lines of epithelial origin. SCLC also metastasize more frequently and earlier than NSCLC. Since paxillin expression is decreased in SCLC and there may be a few NSCLC tumor specimens exhibiting dierent levels of paxillin, it is conceivable that paxillin expression in certain subtypes of lung cancer could be used in prognostication. Prognostic factors are used as determinants to how widespread or aggressive a lung cancer could potentially be. Factors such as clinicopathologic (including clinical observations, tumor size, histological subtype, tumor differentiation, and lymphatic and blood vessel invasion), serum tumor markers (CA-125 and CEA) and molecular markers (oncogenes or tumor suppressors, metastatic propensity markers, dierentiation markers and proliferation markers) are important prognosticators in lung cancer (Strauss, 1997) . A mixture of these factors are used to determine how far along a lung cancer has progressed and can give a general idea as to how the patient may respond to dierent types of therapies. Theoretically, paxillin may be useful as a prognostic factor. The expression of paxillin in SCLC is very low as compared to NSCLC samples. Since SCLC is a more aggressive cancer, this data may point to the fact that paxillin is needed to keep cancerous cells from metastasizing. Future studies on paxillin expression in lung cancers should include its expression in lung cancer samples at dierent stages of the disease.
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In conclusion, we have shown expression of paxillin in NSCLC and decreased expression in SCLC. By overexpression studies, paxillin may play an important role in cell morphology and cell motility. For future studies, it would be useful to identify if there are subsets of lung cancer which can be prognosticated based on paxillin expression. Also, it would be useful to identify which portion of paxillin may be important in cellular dynamics of motility.
Materials and methods
Cell lines, cell culture and tissue samples
The NSCLC and SCLC cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA). NSCLC cells (Calu-1, Calu-3, Calu-6, SK-LU-1, SW900, H520, H661) were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) (Mediatech, Washington, DC, USA), 10% (v/v) fetal calf serum (PAA Laboratories Inc., Newport Beach, CA, USA). SCLC (H69, H128, H209, H82, H345) cells were maintained in RPMI 1640 medium (Mediatech, Washington, DC, USA), 10% (v/v) fetal calf serum. All cell lines were then incubated at 378C with Figure 4 Northern analysis of various NSCLC and SCLC cell lines using paxillin and CRKL as probes. Total RNA was isolated and northern analysis was performed as described under Materials and methods. Cell line RNA is identi®ed above each lane. Top panel, Paxillin as the probe; middle panel, CRKL as the probe; bottom panel, b-actin as a control probe Figure 5 Expression of paxillin is decreased in SCLC cell lines as assessed by immunoblotting. Cell lysates from the various NSCLC and SCLC cell lines were processed as described in Materials and methods. Lysates were applied to a 7.5% SDS ± PAGE gel and transferred to an Immobilon-P membrane. The membrane was initially immunoblotted with anti-phosphotyrosine (4G10) antibody, and thereafter sequentially stripped and reprobed with anti-talin antibody, anti-vinculin antibody, antipaxillin antibody, and ®nally with anti-CRKL antibody. There is decreased amount of p68 paxillin in most SCLC cell lines, with heterogeneity of expression in NSCLC cell lines. The p46 and p33 forms recognized by the anti-paxillin antibody may represent cleaved products of p68 paxillin. The expression of talin, vinculin, and CRKL appears to be similar in the various cell lines 10% CO 2 (Shapiro et al., 1995) . Tissue samples of normal and tumor were obtained by members of the Division of Thoracic Surgery, Brigham and Women's Hospital under IRB approved protocols.
Production of green¯uorescence protein constructs
GFP-paxillin, GFP-PE7 (N-terminal paxillin without the LIM domains) and GFP-LIM expression constructs were prepared in the pEGFP-C1 vector (Invitrogen, Carlsbad, CA, USA). Full length paxillin (human, amino acids 1 ± 557), PE7 (amino acids 1 ± 324) and LIM domains (human, amino acids 325-557) cDNAs were released from the pGEX-3X constructs by digestion with EcoRI (Salgia et al., 1995b) . They were ligated into EcoRI-digested pEGFP- Figure 6 Tyrosine phosphorylation of paxillin in lung cancer cell lines. Lysates from three NSCLC and three SCLC cell lines were generated and processed as described. Paxillin immunoprecipitates were applied to a 7.5% SDS ± PAGE gel and transferred to an Immobilon-P membrane. The membrane was initially immunoblotted with anti-phosphotyrosine antibody (4G10) (A) and thereafter stripped and probed with anti-paxillin antibody, clone 5H11 (B). No tyrosine phosphorylation of paxillin was observed Figure 8 Western blot analysis of paxillin expression in NSCLC tumor tissue samples. Using paired tumor (T) and adjacent normal (N) lung tissue samples from adenocarcinoma, squamous cell, and large cell lung cancer, immunoblotting was performed on extracted lysates. Lysates were prepared as described in Materials and methods. Lysates were applied to a SDS ± PAGE 7.5% gel and transferred to an Immobilon-P membrane. The membrane was immunoblotted with anti-paxillin antibody, thereafter stripped and reprobed with anti-CRKL antibody Figure 7 Northern analysis of paxillin expression in NSCLC tumor tissue samples. Using paired tumor (T) and adjacent normal (N) lung tissue samples from adenocarcinoma, squamous cell, and large cell lung cancer, Northern analysis was performed on total RNA. Each panel was probed using a paxillin probe and b-actin as a control probe C1 vectors to obtain the full length paxillin, PE7 and LIM domains GFP constructs.
Transfection and cell staining
Cells were transfected using LipoFECTAMINE (GIBCO ± BRL, Gaithersburg, MD, USA) essentially as manufacturer's directions with minor modi®cations. Brie¯y, Calu-1 and H661 cells were plated at a density of 1.5610 5 cells per well of a six-well tissue culture plate 24 h before transfection. Two mg of the respective pEGFP constructs and 5 mg of LipoFECTAMINE were diluted separately into 100 ml of OPTI-MEM Reduced Serum Medium (GIBCO BRL) followed by mixing of the DNA and lipid and incubation at room temperature for 60 min. During this incubation, the adherent cells were washed twice with prewarmed, OPTI-MEM medium. OPTI-MEM medium was then added to the DNA-lipid mixture to bring the volume to 1 ml, and the mixture was overlaid onto the cells for a 5 h incubate at 378C. After 5 h, 1 ml of OPTI-MEM with 20% FCS and 1% penicillinstreptomycin was added, and the cells were incubated overnight. The cells were washed twice in complete medium, and then changed to complete DMEM with 1.0 mg/ml G418 (GIBCO ± BRL) after 24 h. After an initial phase of selection, the G418 concentration was reduced to 800 mg/ml for maintenance of enriched populations of transfected cells.
For cell staining, cells were trypsinized and replated on glass coverslips, and processed for immuno¯uorescence analysis as has been described in detail previously (Salgia et al., 1995a) .
Time-lapse video microscopy
Cells were cultured on uncoated plastic tissue culture plates (35-mm plates; Becton Dickinson Labware) in a temperature controlled chamber at 378C in their standard media with air and CO 2 . The cells were examined by video microscopy utilizing a Olympus IX70 inverted microscope, Omega temperature control device, Optronics Engineering DEI-750 video camera, Olympus OEV142 TV and Panasonic AG6740 time-lapse S-VHS video recorder . The digital video images were Large Cell Small Cell H&E Keratin Paxillin Figure 9 Decreased expression of paxillin in SCLC cells by immunoperoxidase staining. Tissue samples from a patient with NSCLC or SCLC were prepared as described in Materials and methods. Slides were stained with anti-paxillin antibody, anti-keratin antibody, or hematoxylin and eosin. Appreciated is the detection of keratin in NSCLC and SCLC; however, there is no staining of paxillin in the SCLC sample captured and printed with a Sony UP5600MD Color Video Printer.
Preparation of cell lysates and immunoblotting
Cell lines were lysed in lysis buer (20 mM Tris, pH 8.0, 150 mM NaCl, 10% glycerol, 1% Nonidet P-40 and 0.42% NaF) containing inhibitors (10 ml of 100 mM phenylmethylsufonyl¯ouride, 10 ml of 100 mM Na 3 VO 4 , 5 ml of aprotinin (Sigma, St Louis, MO, USA) and 2 ml of 10 mg/ml leupeptin in ®nal volume of 1 ml) (Salgia et al., 1995b) . Protein from human tissues was prepared by extracting in TRISOLV according to the manufacturer's directions (GIBCO ± BRL). Cell lysates were separated by 7.5% SDS ± PAGE under reducing conditions, electrophoretically transferred to Immobilon TM polyvinylidene diflouride (Millipore, Bedford MA, USA), and processed for immunoblotting as per established methods using the enhanced chemiluminescense technique (Amersham Corp.) . Immunoblots with various antibodies are as shown under Results. Antibodies used were mouse monoclonal anti-paxillin (clone 5H11, UBI), mouse monoclonal anti-CRKL (clone 5-6), mouse monoclonal anti-phosphotyrosine (clone 4G10, a generous gift from Dr Brian Druker, Oregon Health Science University, Portland, OR, USA), mouse monoclonal anti-talin (clone 8d4, Sigma) and mouse monoclonal anti-vinculin (clone VIN-11-c, Sigma, St Louis, MO, USA).
RNA isolation and Northern analysis
Total RNA from various cell lines and human tissue was obtained by extracting in TRISOLV according to the manufacturer's directions (Gibco Life Sciences). Fifteen mg of each RNA sample was separated by electrophoresis in formaldehyde-agarose gels in 3-(N-morpholino)propanesulfonic acid (MOPS) buer and transferred to a Nylon membrane (GeneScreen, NEN Research Products, Boston, MA, USA). Hybridization probes used for Northern blotting were labeled with 32 P by using the random primed DNA labeling kit (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA). cDNAs for full length paxillin, CRKL (a generous gift of Dr John Groen, Children's Hospital, Los Angeles, CA, USA), and b-actin were used as speci®c probes for northern analysis.
Immunoperoxidase staining
Immunostaining was performed on cryostat sections of tissue using a standard peroxidase-anti-peroxidase method (Sambrook et al., 1989) . Cryostat sections were sequentially ®xed in 2% paraformaldehyde for 5 min and methanol for 10 min. Thereafter, sections were preincubated with goat serum to block nonspeci®c binding and subsequently incubated with the appropriate primary antibody (mouse monoclonal anti-paxillin), rabbit antikeratin, or control immunoglobulin. Endogenous peroxidase was subsequently blocked by immersing the cryostat sections in 1% H 2 O 2 in methanol. Thereafter, secondary antibody was applied, followed by mouse or rabbit peroxidase-anti-peroxidase. All antibody incubations were carried out for 1 h and followed by washes with PBS/0.1% gelatin. Following antibody treatment, samples were subsequently developed with diaminobenzidine-H 2 O 2 , counterstained with hematoxylin, dehydrated in alcohols and xylene and mounted for microscopy.
